Cerebral Rhizomucor Infection Treated by Posaconazole Delayed-Release Tablets in an Allogeneic Stem Cell Transplant Recipient
Open Access
- 1 February 2017
- journal article
- case report
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 55, 24-26
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Similar efficacy of broad-range ITS PCR and conventional fungal culture for diagnosing fungal infections in non-immunocompromised patientsBMC Microbiology, 2016
- Prevention of invasive fungal infections in immunocompromised patients: the role of delayed-release posaconazoleInfection and Drug Resistance, 2015
- Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral SuspensionAntimicrobial Agents and Chemotherapy, 2012
- A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteersJournal of Antimicrobial Chemotherapy, 2012
- Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatmentExpert Review of Anti-infective Therapy, 2011
- Posaconazole concentrations in the central nervous systemJournal of Antimicrobial Chemotherapy, 2008
- Cerebral zygomycosisMycoses, 2005
- Fungal CNS infections in patients with hematologic malignancyExpert Review of Anti-infective Therapy, 2005
- Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported CasesClinical Infectious Diseases, 2005
- Activity of posaconazole in the treatment of central nervous system fungal infectionsJournal of Antimicrobial Chemotherapy, 2005